Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
出版年份 2022 全文链接
标题
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
作者
关键词
-
出版物
Scientific Reports
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-03
DOI
10.1038/s41598-022-10777-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
- (2020) Jean-Jacques Kiladjian et al. Lancet Haematology
- JAK Inhibitors: Prospects in Connective Tissue Diseases
- (2020) Hanxiao You et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor in Patients with Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2020) Michael F. Robinson et al. Arthritis & Rheumatology
- Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
- (2020) Philip Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase
- (2020) Enriqueta Vallejo-Yagüe et al. DRUG SAFETY
- A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
- (2020) Ling Peng et al. Expert Opinion On Drug Safety
- Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
- (2020) Gary R Lichtenstein et al. INFLAMMATORY BOWEL DISEASES
- Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
- (2020) T. Bieber et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies
- (2020) Wenhui Xie et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis
- (2019) John Mascarenhas et al. LEUKEMIA & LYMPHOMA
- Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
- (2019) Wenhui Xie et al. ANNALS OF THE RHEUMATIC DISEASES
- A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
- (2019) Katie Bechman et al. RHEUMATOLOGY
- JAK inhibitors for the treatment of autoimmune and inflammatory diseases
- (2019) Yvan Jamilloux et al. AUTOIMMUNITY REVIEWS
- Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials
- (2019) Ying‐Chou Chen et al. International Journal of Rheumatic Diseases
- Eczema Herpeticum: Clinical and Pathophysiological Aspects
- (2019) Alexia Damour et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
- (2018) Sumit Kunwar et al. CLINICAL RHEUMATOLOGY
- Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
- (2018) Ian C. Scott et al. DRUG SAFETY
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
- (2016) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis
- (2016) Bethany T. Samuelson et al. BLOOD COAGULATION & FIBRINOLYSIS
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
- (2014) Stanley Cohen et al. Arthritis & Rheumatology
- vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues
- (2013) Tomas Bergvall et al. DRUG SAFETY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
- (2011) G Niklas Norén et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Cytokine Signaling Modules in Inflammatory Responses
- (2008) John J. O'Shea et al. IMMUNITY
- A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
- (2008) Allison L Smitten et al. ARTHRITIS RESEARCH & THERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started